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Background: Arrhythmias can appear with a variety of symptoms, all from vague to pronounced and handicapping
symptoms. Therefore, patient-reported outcomes (PROs) concerning symptom burden are important to assess and
take into consideration in the care and treatment of patients with arrhythmias. The main purpose was to develop
and validate a disease-specific questionnaire evaluating symptom burden in patients with different forms of
arrhythmias.
Methods: A literature review was conducted and arrhythmia patients were interviewed. Identified symptoms were
evaluated by an expert panel consisting of cardiologists and nurses working daily with arrhythmia patients. SF-36
and Symptoms Checklist (SCL) were used in the validation of the new questionnaire Arrhythmia-Specific
questionnaire in Tachycardia and Arrhythmia (ASTA).
Homogeneity was evaluated with Spearman´s correlations and Cronbach´s alpha coefficient (α) was used to
evaluate internal consistency. Construct validity was evaluated using item-total correlations and convergent and
discriminant validity. For this, Spearman’s correlations were calculated between the ASTA symptom scale, SCL and
SF-36. Concurrent validity was validated by Spearman´s correlations between the ASTA symptom scale and SCL.
Results: The correlations between the different items in the ASTA symptom scale showed generally sufficient
homogeneity. Cronbach´s α coefficient was found to be satisfactory (α= 0.80; lower bound 95 % CI for α= 0.76).
Construct validity was supported by item-total correlations where all items in the symptom scale were sufficiently
correlated (≥0.3). Convergent and discriminant validity was supported by the higher correlations to the
arrhythmia-specific SCL compared to the generic SF-36. Concurrent validity was evaluated and there were
sufficiently, but not extremely strong correlations found between the ASTA symptom scale and SCL.
Conclusions: The nine items of the ASTA symptom scale were found to have good psychometric properties in
patients with different forms of arrhythmias. Arrhythmia patients suffer from both frequent and disabling symptoms.
The validated ASTA questionnaire can be an important contribution to PROs regarding symptom burden in
arrhythmia patients.
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Heart rhythm disturbances include several forms of
arrhythmias. The most common form is atrial fibrillation
(AF), occurring in 1–2 % of the general population and
with an increasing prevalence in older patients [1–4].
Arrhythmias can appear in recurrent attacks or be inces-
sant, are known to be unpredictable and can appear with
a variety of symptoms, all from vague to pronounced
and handicapping symptoms [4–8].
Descriptions of arrhythmia patients’ symptom burden
often include the disease-specific symptoms, frequency,
duration and severity where particularly frequent attacks
have shown to negatively affect the patient´s life situ-
ation [5–8].
Main goals when treating arrhythmia patients can be
either curative treatment or to achieve symptom relief.
When evaluating disease severity and intervention effi-
cacy it is of great importance to examine not only object-
ive parameters such as ECG-measurements, where also
patient-reported outcomes (PROs) are important to take
into consideration to assess patients’ subjective well-
being and daily life situation [9–12]. Most of the scales
or questionnaires available for assessing PROs in
arrhythmia patients are designed for AF patients separ-
ately, or developed for patients with other supraventricu-
lar arrhythmias [13–21]. The Symptom Checklist,
Frequency and Severity scale (SCL) and the Patient Per-
ception of Arrhythmia Questionnaire (PPAQ) are the
only scales that have been used in a wide range of
arrhythmia patients. SCL is mostly used in AF patients
and PPAQ is designed for other arrhythmias [15,17,21].
Some of the existing questionnaires can be criticized
for mixing symptoms and effects of symptoms in the
same scale, not including frequency and duration of the
episodes and for not examining the presence of the more
aggravating symptoms near syncope and syncope.
To the best of our knowledge there is no validated
symptom burden questionnaire developed for assessing
patient-reported outcomes (PROs) in patients with most
different forms of arrhythmias. For this purpose there
was a lack of a validated disease-specific symptom ques-
tionnaire suitable for most forms of arrhythmias.
Aims
The aims of the study were to develop and validate a
disease-specific symptom questionnaire including a symp-
tom scale for patients with different forms of arrhythmias
and to describe patients’ arrhythmia symptoms.
Methods
The present study is a part of a project aiming to de-
velop and validate a disease-specific questionnaire suit-
able for different forms of arrhythmias, the Arrhythmia-
Specific questionnaire in Tachycardia and Arrhythmias(ASTA). The questionnaire as a whole is developed to
evaluate both symptom burden and the impact of
arrhythmia on a patients’ Health-Related Quality of Life
(HRQOL). In this article the development and validation
of the symptom part, including a symptom scale are
described.The Regional Ethical Review Board at the Fac-
ulty of Health Sciences, Linköping, Sweden, approved
the protocol and gave permission for obtaining a verbal
informed consent from the participants. Study participa-
tion was documented in the patient’s medical record.
The study complies with the Declaration of Helsinki
[22,23]. (Number: M170-08 T111-08).
The development phase
To identify representative symptoms covering different
forms of arrhythmia, a comprehensive literature review
was conducted in Medline.
In addition, approximately 300 patients with different
forms of arrhythmias (most with supraventricular but
also some with ventricular arrhythmias) referred for
radiofrequency ablation (RFA) were interviewed about
their symptoms in connection with arrhythmia episodes.
The interviews were conducted before the ablation pro-
cedure using a structured questionnaire guide.
From the results items were created by the first author
in collaboration with an electrophysiologist.
The ASTA questionnaire was distributed to 6–8 cardi-
ologists, 8–10 nurses at each time of evaluation and over
100 patients were approached by the first author during
the development phase, in addition to the interviews.
The symptoms were approved with two changes, one
was a complementary explanation recommended for the
symptom cold sweat to avoid misinterpretation. The
symptom pressure in the chest was extended to be com-
bined with “discomfort”. Based on the identified symp-
tom, a symptom burden scale was created.
The selected symptoms then were: breathlessness dur-
ing activity, breathlessness even at rest, dizziness, cold
sweat, pronounced tiredness, chest pain, pressure/dis-
comfort in chest and worry/anxiety. Three symptoms
remained outside the scale; tiredness after having
arrhythmia, experiences of near syncope and syncope in
connection with the arrhythmia episode.
Symptoms of palpitation, duration and frequency of
the arrhythmia attacks were questioned for, also outside
the scale.
In the initial phase, the ASTA symptom questionnaire
was used in over 500 patients with different forms of
arrhythmias: AF and atrial flutter (AFL) patients sched-
uled for DC-conversion, AF patients randomized to
treatment with anti-arrhythmic drugs in comparison to
RFA [24] and patients treated with RFA due to AV-Nodal
reentry tachycardia (AVNRT), Wolff-Parkinson-White
syndrome (WPW), focal atrial tachycardia (FAT), atrial
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or His bundle catheter ablation, as well as patients with
ventricular arrhythmias (PVCs or VT). The patients were
approached when they came for their scheduled inter-
vention, for example DC-conversion, many due to RFA,
or to out-patient clinics for scheduled study visits.
Patients were encouraged to comment and suggest
additional symptoms if needed. This process resulted in
two more symptoms being added to the scale, weakness
and infirmity. The symptom worry/anxiety was reworded
to “worry” and the vocabulary ”tachycardia attacks” was
changed to “heart rhythm disturbance ” to be suitable for
patients with attacks, frequent extra beats or with per-
sistent arrhythmias. The extended 10 item scale was
again reviewed and confirmed by the expert panel. Dur-
ing the initial phase a four-point response scale was con-
structed and reviewed by patients, with the response
alternatives ranging from 0 to 3: “No (0), Yes to a certain
extent (1), Yes, quite a lot (2) or Yes, a lot (3)“ where a
higher score implied higher symptom burden.
Concerning the recall time, patients were asked for
their most recent experience of arrhythmia symptoms,
normal duration of their arrhythmia and length of time
of the longest episode. The patients were also asked to
estimate the number of occasions they had experienced
arrhythmia during the three month period prior to com-
pleting the questionnaire. No further recall time was
requested in the questionnaire.
The validation phase
Patient population and inclusion criteria
The study inclusion period lasted from May 2009 until
late December 2009. Patients eligible for study participa-
tion were those referred for RFA treatment with the
same diagnoses reported for the initial phase at a Univer-
sity Hospital and patients seeking acute care due to AF
at two County Hospitals in Sweden. The RFA patients
were consecutively asked about participation and the
out-patients were conveniently asked at the time for the
acute care visit. Patients were included if they met the
inclusion criteria: to be referred for RFA treatment due
to different forms of arrhythmias or seeking emergency
care due to AF, willing to participate in the study, age
≥18 years, with sufficient knowledge of the Swedish lan-
guage and capable to independently fill in the study
questionnaires.
Procedures
All RFA patients received posted study information be-
fore the intervention and got study information at the
time of admission to hospital, before the scheduled inter-
vention. The acute care AF patients received information
at the time of their hospital visit. Together with the
questionnaires the patients received instructions on howto complete the questionnaires and were encouraged to
ask for help if needed. The questionnaires were com-
pleted mostly the day before treatment in RFA patients
and for the out-patients at the time of the acute care
visit.
Questionnaires for patient-reported outcomes
The patients completed three questionnaires in the
study; The Arrhythmia-Specific questionnaire in Tachy-
cardia and Arrhythmia (ASTA see appendix), Symptom
Checklist, Frequency and Severity scale (SCL version 3)
and MOS 36-Item Short-Form Health Survey (SF-36 ver-
sion 1.0).
Symptom Checklist, Frequency and Severity scale
The SCL is a disease-specific checklist measuring
arrhythmia-related symptoms and patients' perception of
the frequency and severity of the arrhythmia during the
last month. The SCL is mostly used in patients with
atrial fibrillation describing arrhythmia-related symp-
toms, but has also been used in patients with other
forms of tachycardia treated with RFA. The SCL consists
of 16 items for symptom frequency and scores from 0 to
64 (from never having the symptoms to always having
the symptoms) and with 16 items for symptom severity
scoring from 0 to 48 (mild to extreme). The higher the
frequency score, the greater frequency with which symp-
toms are experienced and the higher the severity score
the greater severity of the symptoms experienced, i.e.
lower scores represent better status [15,17,25].
MOS 36-Item Short-Form Health Survey
The SF-36 was used to assess general health. SF-36 com-
prises 35 items grouped into eight scales and one ques-
tion concerning changes in health. The eight scales
represent physical functioning (PF), role limitations due
to physical health problems (RP), bodily pain (BP), gen-
eral health (GH), vitality (energy/fatigue (VT)), social
functioning (SF), role limitations due to emotional pro-
blems (RE) and mental health (psychological distress and
psychological well-being (MH)). The eight scales are
summarized in two dimensions, physical and mental
component summary (PCS/MCS). For each of the eight
scales and the two dimensions, scores were coded,
summed and transformed to a scale ranging from 0
(worst possible health) to 100 (best possible health). The
scoring in SF-36 data was carried out as described by
Ware and colleagues [26–29].
Statistical analysis
Means, standard deviations and frequencies were used to
describe the characteristics of the sample and patient
symptoms. The ASTA symptom burden questionnaire
was psychometrically evaluated regarding data quality,
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consistency reliability.
Data quality was evaluated regarding score distribution
and missing data pattern. Frequencies were used to
evaluate the distribution of item responses while the
Kolmogorov-Smirnov test was used to evaluate if the score
in the ASTA symptom scale deviated from a normal dis-
tribution. Frequencies were used to describe the missing
data pattern and to describe floor and ceiling effects.
Floor and ceiling effects were defined if the majority of
scores were distributed at either end of the response
scale [30].
Homogeneity between the symptoms was evaluated
with Spearman´s correlations (rs), and internal consis-
tency reliability was evaluated with Cronbach´s alpha
coefficient (α) in the ASTA symptom scale [30,31]. An
α coefficient ≥0.70 was considered sufficient. In addition,
a lower bound confidence interval (95 %) for Cronbach´s
alpha was calculated [30,31].
Construct validity was evaluated using item-total cor-
relations adjusted for overlaps and an acceptable level
was set to ≥0.30 [30]. Convergent and discriminant valid-
ity were evaluated and for this purpose Spearman’s cor-
relation coefficients were used. To support convergent
and discriminant validity the ASTA symptom scale was
hypothesized to correlate more strongly with SCL’s
frequency and severity scales compared to the scales in
SF-36.
Concurrent validity was established by Spearman’s cor-
relations between the ASTA symptom scale and the SCL
frequency and severity scales.
A p-value of <0.05 was considered significant. Statis-
tical analyses were conducted using SPSS 18 for
Windows (SPSS, Inc., Chicago, IL) and Stata 11.1 for
Windows (Stata Corporation, College Station, TX).
Results
Patient demographics
There were 270 patients included in the validation study,
215 RFA patients and 55 patients seeking emergency
care due to AF. The majority of patients were men
(66 %) with a mean age of 59 years (range 18–89 years).
Beta blockers was the most frequently used anti-
arrhythmic medication (59 %), most patients (83 %) were
cohabitants and more than half of the patients (63 %)
had an educational level of upper secondary school cer-
tificate or more, including university degrees (Table 1).
Data quality
Two symptoms, cold sweat and chest pain, met the cri-
teria for floor effect. No symptom showed ceiling effect.
The mean score for the 10 item ASTA symptom scale
was 12.2 (SD 5.5) and the scores were normally distribu-
ted according to the Kolmogorov-Smirnov test(p = 0.252). Missing data were equally distributed across
scale items and were represented by 20 patients having
missing answers in all ten items of the scale, one patient
with nine missing answers, one had eight missing
answers and the other 18 patients had between 1–3
missing answers each.Homogeneity and internal consistency reliability
Homogeneity between the 10 items in the ASTA symp-
tom scale was reflected by significant correlations be-
tween the items except for three symptoms: worry and
breathlessness during activity, infirmity and chest pain
and lastly, infirmity and pressure/discomfort in chest.
The rest of the items were significantly correlated
with the strongest correlation between the symptoms in-
firmity and weakness (Table 2). These correlations lead
to a revised symptom scale with 9 items, combining
weakness/infirmity in one question. The internal con-
sistency was found to be satisfactory high for the revised
9 item scale (α= 0.80) (Table 3) and lower bound confi-
dence interval for Cronbach’s α was satisfactory as well
(α= 0.76).
The association between symptoms outside the ASTA
symptom scale and symptoms in the scale demonstrated
one strong correlation and this was between the symp-
toms exploring tiredness; tiredness afterwards and pro-
nounced tiredness during arrhythmia (rs> 0.6) (Table 2).Construct validity
The 9 items in the revised symptom scale reached the
expected level of item-total correlations, ranging from
0.35 (worry) to 0.59 (breathlessness even at rest), indicat-
ing the items measuring the same concept (Table 3).
Convergent and discriminant validity was demon-
strated for the ASTA symptom scale where the correla-
tions were more strong with the SCL frequency and
severity scales (rs> 0.60) than with the scales in SF-36,
supporting convergent validity. The ASTA symptom
scale correlated weaker but significantly (rs< 0.60) with
the SF-36 eight scales and physical and mental compo-
nent summary, supporting discriminant validity (Table 4).
Strong correlations were found between the SCL scales
and the scales in SF-36. The lowest correlation was seen
for role-emotional and the SCL severity scale, rs =0.43,
and strongest correlation, rs =0.70 for vitality and the
SCL frequency scale.Concurrent validity
Concurrent validity was demonstrated with strong corre-
lations (rs> 0.60) between the ASTA symptom scale and
both scales in the SCL frequency and severity scales
(Table 4).
Table 2 Correlations between arrhythmia-specific symptoms in ASTA
ASTA 1 2 3 4 5 6 7 8 9 10 11 12 13
1 Breathlessness during activity 1
2 Breathlessness even at rest 0.60*** 1
3 Dizziness 0.20** 0.26*** 1
4 Cold sweat 0.21** 0.28*** 0.32*** 1
5 Pronounced tiredness 0.42*** 0.34*** 0.34*** 0.29*** 1
6 Chest pain 0.23*** 0.27*** 0.35*** 0.24*** 0.20** 1
7 Pressure/ discomfort in chest 0.28*** 0.39*** 0.28*** 0.24*** 0.18** 0.57*** 1
8 Worry 0.07ns 0.17** 0.21** 0.16* 0.24*** 0.16* 0.21** 1
9 Weakness 0.40*** 0.36*** 0.33*** 0.33*** 0.60*** 0.13* 0.16* 0.26*** 1
10 Infirmity 0.41*** 0.30*** 0.31*** 0.31*** 0.64*** 0.10ns 0.11ns 0.31*** 0.68*** 1
11 Near syncope 0.24*** 0.14* 0.44*** 0.20** 0.19** 0.14* 0.09ns 0.08ns 0.22** 0.18** 1
12 Syncope 0.10ns 0.02ns 0.10ns 0.09ns 0.14* 0.11ns 0.05ns 0.12ns 0.07ns 0.11ns 0.47*** 1
13 Tiredness afterwards 0.22** 0.23** 0.30*** 0.27*** 0.62*** 0.29*** 0.23** 0.16* 0.43*** 0.46*** 0.09ns 0.04ns 1
Statistic correlation analyses were performed using Spearman´s correlation coefficient.
*** p< 0.001, **p< 0.01 and *p< 0.05, ns = not significant.
Table 1 Characteristics of the participants
































GenderF/M(M %) 93/177(66) 23/17(43) 8/8(50) 5/3(38) 1/3(75) 3/13(81) 33/93(74) 0/5(100) 20/35(64)
Cohabitant/living
alone(cohabit. %) 1






26(10) 3(7.5) 1(6) 0 1(25) 0 10(8) 0 11(20)
Compulsory
school certificate
71(26) 14(35) 2(13) 4(50) 0 2(13) 34(27) 0 15(27)
Upper secondary
school certificate
96(36) 11(28) 9(56) 3(38) 3(75) 7(44) 44(35) 2(40) 17(31)
College/University
degree
73(27) 11(28) 4(25) 1(13) 0 7(44) 36(29) 3(60) 11(20)
Medication 3
Class I(%) 46(17) 0 1(6) 0 0 0 38(30) 0 7(13)
Class II(%) 159(59) 16(40) 6(38) 3(38) 2(50) 10(63) 81(64) 2(40) 39(71)
Class III(%) 41(15) 4(10) 0 2(25) 2(50) 1(6) 27(21) 2(40) 3(6)
Class IV(%) 36(13) 1(3) 0 0 2(50) 0 24(19) 0 9(16)
Digitalis(%) 20(7) 0 1(6) 1(13) 0 1(6) 10(8) 1(20) 6(11)
AVNRT =AV-Nodal reentry tachycardia, WPW=Wolff-Parkinson-White syndrome, FAT = focal atrial tachycardia, atrial macro-reentry, AFL atrial flutter, AF = atrial
fibrillation, AF patients with out-patient visits in emergency room. Ventricular arrhythmia includes ventricular tachycardia and VES = Ventricular extra beats.
RFA= radiofrequency ablation.
1 2 missing values.
2 4 missing values.
3 Here, medication is anti-arrhythmic medication where one patient can have more than one drug.
Class I represents flecainide/propafenon, class II beta blockers, class III amiodarone/sotalol, and class IV calcium channel blockers.
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Table 3 Data quality and item-total correlations for ASTA symptom scale
































0.496 0.808 1.79(0.98) 0.479 0.777 1.79(0.98) 24(9) 75(28) 73(27) 70(26)
Breathlessness
even at rest
0.569 0.801 0.77(0.81) 0.588 0.762 0.77(0.81) 105(39) 107(40) 22(8) 11(4)
Dizziness 0.468 0.810 0.86(0.79) 0.465 0.778 0.86(0.79) 87(32) 116(43) 33(12) 10(4)
Cold sweat 0.455 0.813 0.97(0.98) 0.450 0.781 0.97(0.98) 100(37) 76(28) 48(18) 22(8)
Pronounced
tiredness
0.604 0.795 1.74(0.98) 0.544 0.767 1.74(0.98) 26(10) 75(28) 79(29) 65(24)
Chest pain 0.431 0.814 0.56(0.74) 0.465 0.778 0.56(0.74) 134(50) 91(34) 14(5) 7(3)
Pressure/discomfort
in chest
0.428 0.814 1.01(0.88) 0.461 0.778 1.01(0.88) 74(27) 116(43) 37(14) 18(7)
Worry 0.367 0.820 1.29(0.86) 0.348 0.793 1.29(0.86) 39(14) 125(46) 57(21) 27(10)
Weakness 0.650 0.792 1.54(0.86) 0.585 0.762 1.54(0.86) 21(8) 115(43) 73(27) 38(14)








1 n = 230.
2 n = 242–247, the number of missing answers varied between 23–28 for the different items in the 10 item scale.
Table 4 Correlations between ASTA symptom scale, SCL
and SF-36
1 2 3
1 ASTA 1Symptomscale 1
2 SCL Frequency 0.62*** 1
3 Severity 0.61*** 0.94*** 1
4 SF-36 PF −0.32*** −0.57*** −0.56***
5 RP −0.25*** −0.50*** −0.49***
6 BP −0.39*** −0.48*** −0.55***
7 GH −0.29*** −0.47*** −0.45***
8 VT −0.44*** −0.70*** −0.63***
9 SF −0.31*** −0.51*** −0.49***
10 RE −0.32*** −0.46*** −0.43***
11 MH −0.33*** −0.59*** −0.53***
12 PCS −0.29*** −0.54*** −0.55***
13 MCS −0.36*** −0.54*** −0.50***
1 The revised ASTA symptom scale with 9 items. Statistic correlation analyses
were performed using Spearman´s correlation coefficient. *** p< 0.00.
SCL symptom frequency and severity scale. The eight scales in the SF-36
includes PF = Physical Functioning, RP = Role-Physical, BP = Bodily Pain,
GH=General Health, VT = Vitality, SF = Social Functioning, RE = Role-Emotional,
MH=Mental Health and PCS = Physical Component Summary, MCS =Mental
Component Summary.
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The most commonly reported symptoms by the patients
were weakness, infirmity and breathlessness during activ-
ity and pronounced tiredness, and these symptoms were
also the most burdensome for the patients (mean ≥1.5,
Table 3). Chest pain, breathlessness even at rest, dizzi-
ness and cold sweat were the symptoms more seldom
reported and less burdensome for the patients (mean
≤1.0, Table 3). The patients were asked about experiences
of palpitation during arrhythmia episodes and many of
the patients felt rapid heart rhythm (71 %), most experi-
enced the arrhythmia as being irregular (61 %) . Com-
mon during arrhythmia episodes was a feeling of harder
heart beats (43 %) and missing beats (45 %). The patients
were also asked to estimate the duration of their
arrhythmia and most common were episodes shorter
than seven hours (40 %), but some (12 %) had duration
of more than 48 hours. The frequency of arrhythmia
during the three month period before treatment varied
between not having any arrhythmia at all (8 %) to having
episodes more often than 15 occasions or experiences of
arrhythmia daily (36 %). Many patients were tired after-
wards (74 %) and some of the patients had experienced
the more disabling symptoms near syncope and syncope
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arrhythmia.
Thirty percent of the patients answered that the
arrhythmia appeared on special occasions. The occasions
mentioned were: At stress, during nights, at effort/
physical activities, rapid movements, anxiety, when
angry, when forgotten the medication. Seventeen percent
answered “yes” to food or drinks as having an influence
on arrhythmia appearance. Most commonly contributing
to the onset of the arrhythmia was alcohol, then coffee,
but fat or spicy foods and eating too much was also
mentioned. More than half of the patients, 52 %, were
not able to interrupt the arrhythmia by self-management
after the onset.
Discussion
The new ASTA symptom questionnaire showed gener-
ally good reliability and validity properties.Strengths with
the study were the amount of patients and the repeated
expert panel evaluations. This increases the possibility to
have covered the most relevant and commonly experi-
enced symptoms and to have achieved a scale with good
sensitivity [32]. Although the ASTA symptom scale
includes rather few symptoms the scale is likely to have
sufficient coverage and relevance in different forms of
arrhythmias. Too few items increases the risk for loss of
information, on the contrary too many can lead to a risk
for measuring the same construct but in a slightly differ-
ent way and make it burdensome to complete [33].
Data skewness was not a problem even though two
symptoms showed floor effect and the symptoms showed
good item-total correlation to the symptom scale [30].
The concerns about floor and ceiling effects is regarding
the ability to discriminate between healthier patients and
patients with more severe conditions and also difficulties
with sensitivity and responsiveness to changes [32]. The
scale had an overall good distribution of the scores, im-
plying the symptoms being able to discriminate between
patients with a high respectively low symptom burden.
The missing data pattern showed an equal distribution
of missing values. Except those with missing values for
all the symptoms in the symptom scale, the overall miss-
ing data was low [32]. Some of the patients did not ex-
perience distinct arrhythmia-related symptoms and were
therefore not motivated to complete the questionnaire.
This was the case in an earlier validation study where
patients were asked about limitations in working capabil-
ity and where rather many had difficulties to respond be-
cause they were retired [16].
The correlations between the items in the ASTA symp-
tom scale showed generally satisfactory homogeneity. All
items correlated to the total scale and the internal
consistency was sufficiently as well as the lower bound
confidence interval for Cronbach’s α. A reasonableexplanation for the strong correlation between infirmity
and weakness was that these two probably described al-
most the same concept. In the literature there are items
described as causal or effect indicators and there is an
ongoing debate concerning different types of scales,
clinimetric and psychometric scales [32,34,35]. Causal
indicators can be symptoms that affect QoL and scales
can be described as symptom scales including a variety
of items, not to be expected to satisfy the same demands
as for psychometric scales [32,34]. However, many items
may be both causal and effect in nature and statements
concerning distinctions between different scales have
been criticized to be just confusing and limiting [35,36].
We still emphasize that homogeneity matters as the
ASTA symptom scale aims to measure the concept
symptom burden.
Construct validity was supported by the sufficient
item-total correlations where all except one reached the
more stringent criteria suggested for final testing of
scales (>0.4) [32]. Convergent and discriminant validity
are important aspects of construct validity [32,35]. We
expected a stronger correlation between the ASTA
symptom scale and the arrhythmia specific SCL and sig-
nificant but weaker correlations with the generic SF-36,
the latter because both explore physical and mentally-
related domains [16,37–39].
At the time of the validation of ASTA, SCL was the
most well-known and commonly used questionnaire in
arrhythmia patients and therefore also chosen to repre-
sent the “golden standard” for criterion validity.
The hypothesis was confirmed but we had however
expected to find an even stronger correlation between
ASTA and the two scales within SCL. Further we found
that SCL had a strong correlation with one subscale in
SF-36. This can be explained by that SCL includes more
general symptoms, for example headache, poor appetite,
nausea and also consequences on patients’ daily life such
as problems to concentrate and difficulty to sleep
whereas the ASTA symptom scale was developed for
assessing arrhythmia-specific symptoms [15,17,25]. Over-
all, rather strong correlations were found between SF-36
and the SCL scales supporting the more general nature of
the symptoms in SCL. However, the most pronounced
correlation was seen between the two scales within SCL,
indicating the two separate scales measuring almost the
same concept.
More than one third of the patients in the validation
study had been near syncope and more than every 10th
patient had experienced syncope in connection with
arrhythmia, and it would have been valuable to further
explore how often the patients had suffered from these
disabling symptoms, but this information is unfortu-
nately not available. Presence of severe symptoms in
arrhythmia patients has been described in earlier studies
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leading to self-imposed daily life restrictions [7,40].
The patient groups aimed to be covered by the ASTA
questionnaire were included in the validation process. How-
ever, in some groups there were few patients and therefore,
it was not relevant to examine know-groups validity.
During a development phase it is natural and import-
ant to make relevant changes but unfortunately this
reduced the number of patients available for inclusion in
the validation study.
Even if the symptom items in ASTA are relevant and
not too lengthy and probably not too burdensome for
the patients, there will be a need for a system to handle
missing data. We did not want to make any imputation
because this is a validation study but we have rewritten
the patients’ user instructions to more clearly state how
to complete the questionnaire.
The initial tests with the combination of worry/anxiety
(within the initial phase not reported here) showed
higher internal consistency and item-total correlation for
the combination and for the revised ASTA symptom
scale these symptoms will be reworded to asking for
worry/anxiety. In the revised ASTA we further ask for
tiredness in connection with arrhythmia and have erased
the wording pronounced because the answer alternatives
already give the grade of severity, i.e. if it is pronounced
or not. Tiredness after having arrhythmia was commonly
experienced but excluded in the revised version, where
the remaining symptoms are all asked for in connection
with the arrhythmia episodes.
Treatment options have been extensively developed
during the last decades with upgraded international
guidelines and new anti-arrhythmic agents available
[1–3,41]. It is important to assess frequently experienced
symptoms and also the most distressing symptoms for
the patients.
Interventions can be curative or preliminarily expected
to affect the symptom burden with medical treatment,
sometimes life-long, to achieve freedom and relief from
symptoms and for improving the patient’s daily life [4].
Instead of focusing solely on ECG-measurement out-
comes the primary goal must be the patient’s well-being,
the relief of symptoms or symptom control. What are we
treating, the patient or the ECG? [12].
Measurement of subjective well-being is essential in
order to explore the severity of a disease and to evaluate
therapeutic efficacy both in clinical and research settings
[9,10].
The ASTA symptom questionnaire was developed to-
gether with the experts themselves e.g. the arrhythmia
patients and health care professionals with long time
experiences of working with arrhythmia patients.For the usefulness of ASTA as a working tool in clinical
practice and for research settings we have striven for user
friendly instructions. The instructions clearly guide the
patients how to respond if they feel symptomatic or not.
We have performed several of the recommended psycho-
metric analyses to see to the reliability and validity of the
new questionnaire, but it needs to be further tested to con-
firm test-retest reliability and responsiveness to changes.
Even if there are some newly developed questionnaires
[13,16,21,37] since the start of the ASTA project none of
them evaluates symptom burden in most of the existing
forms of arrhythmia.
The advantages with the new ASTA symptom burden
questionnaire are that it is suitable for most forms of
arrhythmias, assesses symptom burden separately and
includes not solely different symptoms, but also the dur-
ation and the frequency of the episodes. In the ASTA
questionnaire both commonly experienced symptoms as
well as less frequent but severe and distressful symptoms
are thoroughly evaluated.
So far only the Swedish version has been validated but
hopefully, in cooperation with the corresponding author,
the questionnaire will be properly forward-backward
translated and validated in several other languages.
Conclusions
The ASTA symptom scale was found to have good psy-
chometric properties in patients with different forms of
arrhythmias. Arrhythmia patients suffer from both fre-
quent and disabling symptoms and PROs are important
to assess, when evaluating these patients’ life situation.
The newly validated ASTA questionnaire can be an im-
portant contribution to PROs in arrhythmia patients.
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